101314-97-0 Usage
Uses
Used in Pharmaceutical Industry:
Simvastatin, Sodium Salt is used as an antilipemic agent for reducing plasma cholesterol levels in rats and dogs. It is a competitive inhibitor of HMG-CoA reductase, which plays a crucial role in cholesterol synthesis.
Used in Cancer Research:
Simvastatin, Sodium Salt is used as a research tool for studying the suppression of TNF-induced NF-κB activation, potentiation of apoptosis in human myeloid leukemia cells, inhibition of glutathione peroxidase 4 (GPX4) activity, and induction of ferroptosis in breast cancer cells.
Used in Treatment of Dyslipidemias:
Simvastatin, Sodium Salt is used in formulations for the treatment of dyslipidemias, a group of disorders characterized by abnormally high levels of lipids in the blood, which can lead to cardiovascular diseases.
in vitro
previous study found that simvastatin could inhibit the incorporation of 14c-acetate to 14c-sterol with an ic50 value of 15 nm in cultured hep g2 cells. in addition, simvastatin was found to be a potent inhibitor of cholesterol synthesis in cultured liver cells, whereas pravastatin inhibited cholesterol synthesis in liver cells only after these cells had been digested by collagenase [1].
in vivo
animal study showd that rats orally dosed with simvastatin had lower plasma cholesterol levels after 4 days of treatment. at the level of 0.02% of the diet, simvastatin lowered plasma cholesterol levels in rats by 64%. moreove, in dogs, simvastatin at a daily oral dosage of 8 mg/kg lower levels of plasma cholesterol. at this dosage, simvastatin was slightly more potent than lovastatin and the levels of plasma cholesterol in these dogs returned to pretreatment levels after stopping the treatment [1].
references
[1] chao, y. ,chen, j.s.,hunt, v.m., et al. lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. european journal of clinical pharmacology 40, s11-s14 (1991).[2] s martande s, kumari m, pradeep ar, pal singh s, kumar suke d. ncomparative evaluation of efficacy of subgingivally delivered 1.2% atorvastatin and 1.2% simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. j dent res dent clin dent prospects. 2017 winter;11(1):18-25.
Check Digit Verification of cas no
The CAS Registry Mumber 101314-97-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,3,1 and 4 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 101314-97:
(8*1)+(7*0)+(6*1)+(5*3)+(4*1)+(3*4)+(2*9)+(1*7)=70
70 % 10 = 0
So 101314-97-0 is a valid CAS Registry Number.
101314-97-0Relevant articles and documents
Nitrate NO donor-type statin derivatives and preparation method thereof
-
Paragraph 0058-0062, (2019/10/01)
The invention discloses nitrate NO donor-type statin derivatives and a preparation method thereof, and belongs to the technical field of medicinal chemical synthesis. The nitrate NO donor-type statinderivatives adopt a structural formula shown as a genera
Furoxan azoxyNO donor type tadine derivative and preparation method thereof (by machine translation)
-
Paragraph 0110; 0112; 0113, (2019/10/01)
The invention discloses a furoxan azoxyNO donor type tadine derivative and a preparation method, and belongs to the technical field of chemical synthesis of medicines: the invention has the following structural formula shown in the general formula. Wherein. In addition, coumaric acid is selected as a connecting base, so that the curative effect; in addition, the compound disclosed by the invention can effectively release NO, and beneficial attempts are made for development of NO donor anti-atherosclerotic drugs in an external mode, and the method has the advantages of effectively improving the curative effect of drugs. 4 - R1 R2 (by machine translation)
Lov-D acyltransferase mediated acylation
-
, (2016/08/17)
Methods for the improved acylation of chemical substrates using LovD acyltransferases, thioesters having acyl groups, and (i) thiol scavengers and/or (ii) precipitating agents are presented. An improved method for the production of simvastatin using (i) activated charcoal as a thiol scavenger and/or (ii) ammonium hydroxide as a precipitating agent is also presented.
Parmaceutical
-
Page/Page column 4, (2008/06/13)
Use of one or more prenylation inhibitors, cholesterol biosynthesis inhibitors or HMG-CoA reductase inhibitors in the manufacture of a medicament for the treatment of hepatitis C virus (HCV) infection. The invention also encompasses a pharmaceutical composition for use in the treatment of HCV infection, the pharmaceutical composition comprising one or more agents capable of inhibiting prenylation, cholesterol biosynthesis or HMG-CoA reductase in the liver, wherein the one or more agents is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
3-KETO HMG-CoA reductase inhibitors
-
, (2008/06/13)
Processes and intermediates are disclosed for the formation of compounds of formula (I) and (II): STR1
Antihypercholesterolemic agents
-
, (2008/06/13)
Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) or (II):
